The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of ...
The U.S. Food and Drug Administration (FDA) this month approved a new nasal spray therapy for acute treatment of migraine. In a press release, the biopharmaceutical company Impel NeuroPharma announced ...
RA’ANANA, ISRAEL - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech company with a market capitalization of $4.84 million, announced Tuesday that its PL-14 Allergy Blocker demonstrated over 60% ...
Investing.com -- Polyrizon Ltd. (NASDAQ:PLRZ) stock surged 41% following the announcement of encouraging preclinical results for its PL-14 Allergy Blocker, which demonstrated targeted deposition in ...
Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon” or the "Company”), a biotechnology company focusing on the development of intranasal products, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback